What is the current Price Target for the ZIOPHARM Oncology, Inc. stock?

The average ZIOPHARM Oncology, Inc. target price is $1,125.00. This is 55,047.10% higher than the current stock price. 1 Analyst has issued a ZIOPHARM Oncology, Inc. price target 2025.

How high will the ZIOPHARM Oncology, Inc. stock rise?

No reliable answer can be given as to how high the ZIOPHARM Oncology, Inc. stock will rise. The performance of stocks, including the ZIOPHARM Oncology, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the ZIOPHARM Oncology, Inc. stock today?

The performance of ZIOPHARM Oncology, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the ZIOPHARM Oncology, Inc. stock fall?

The decline in ZIOPHARM Oncology, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

ZIOPHARM Oncology, Inc. Forecast, price target & analysts

$2.04

0.49%

Nasdaq, Fri, Nov 01 2024

ISIN

US98973P1012

Symbol

ZIOP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts Strategies

ZIOPHARM Oncology, Inc. Target price 2024 - Analyst rating & recommendation

ZIOPHARM Oncology, Inc. Classifications & Recommendation:

Hold

100%

ZIOPHARM Oncology, Inc. Price Target

Target Price	$1,125.00
Price	$2.04
Potential	55,047.10% register free of charge
Number of Estimates	1

	1 Analyst has issued a ZIOPHARM Oncology, Inc. price target 2025. The average ZIOPHARM Oncology, Inc. target price is $1,125.00. This is 55,047.10% register free of charge higher than the current stock price.
	A rating was issued by 2 analysts: 0 Analysts recommend ZIOPHARM Oncology, Inc. to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the ZIOPHARM Oncology, Inc. stock has an average upside potential 2025 of 55,047.10% register free of charge . Most analysts recommend the ZIOPHARM Oncology, Inc. stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-21.97	-0.60
	741.76%	97.27%
P/E		negative

1 Analysts have issued a ZIOPHARM Oncology, Inc. forecast for earnings per share. The average ZIOPHARM Oncology, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$-21.97	741.76%
2024	$-0.60 97.27% Unlock

Current	-0.17	69.09%
2024	-3.10 1,723.53% Unlock

ZIOPHARM Oncology, Inc....

Discover more stocks with a high price target

Valneva 207.78%

CureVac N.V. 152.80%

Plug Power Inc. 89.59%

Moderna 67.08%

ThyssenKrupp 57.97%

Evotec 47.96%

Bavarian Nordic 47.59%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now